Cardosal 20 - Instructions For Use, Reviews, Analogs, The Price Of Tablets

Table of contents:

Cardosal 20 - Instructions For Use, Reviews, Analogs, The Price Of Tablets
Cardosal 20 - Instructions For Use, Reviews, Analogs, The Price Of Tablets

Video: Cardosal 20 - Instructions For Use, Reviews, Analogs, The Price Of Tablets

Video: Cardosal 20 - Instructions For Use, Reviews, Analogs, The Price Of Tablets
Video: Top 5 Best Tablets Under 30000 ⚡ December 2020 2023, April

Cardosal 20

Cardosal 20: instructions for use and reviews

  1. 1. Release form and composition
  2. 2. Pharmacological properties
  3. 3. Indications for use
  4. 4. Contraindications
  5. 5. Method of application and dosage
  6. 6. Side effects
  7. 7. Overdose
  8. 8. Special instructions
  9. 9. Application during pregnancy and lactation
  10. 10. Use in childhood
  11. 11. In case of impaired renal function
  12. 12. For violations of liver function
  13. 13. Use in the elderly
  14. 14. Drug interactions
  15. 15. Analogs
  16. 16. Terms and conditions of storage
  17. 17. Terms of dispensing from pharmacies
  18. 18. Reviews
  19. 19. Price in pharmacies

Latin name: Cardosal 20

ATX code: C09CA08

Active ingredient: olmesartan medoxomil (Olmesartan medoxomil)

Producer: Daiichi Sankyo Europe, GmbH (Germany)

Description and photo update: 2019-12-07

Prices in pharmacies: from 554 rubles.


Film-coated tablets, Cardosal 20
Film-coated tablets, Cardosal 20

Cardosal 20 is a hypotensive drug, angiotensin II receptor antagonist.

Release form and composition

The drug is produced in the form of film-coated tablets: round, biconvex, white, on one side with an imprint "C14", with a specific subtle odor (14 pcs. In blisters, in a cardboard box 1, 2, 4 or 7 blister packs together with instructions for use of Cardosal 20).

Composition for one tablet:

  • active ingredient: olmesartan medoxomil - 20 mg;
  • auxiliary components: hyprolosis with a low degree of substitution, hyprolosis with a viscosity of 6–10 mPa × s, lactose monohydrate, magnesium stearate, microcrystalline cellulose;
  • film shell: talc, titanium dioxide, hypromellose with a viscosity of 5 mPa s.

Pharmacological properties


Olmesartan medoxomil is a potent specific antagonist of angiotensin II receptors (AT 1 receptors). Angiotensin II is the primary vasoactive hormone of the RAAS (renin-angiotensin-aldosterone system). Due to its effect on AT 1 receptors, it plays an important role in the mechanism of arterial hypertension. It is assumed that olmesartan medoxomil blocks all actions of the hormone angiotensin II, which are mediated by AT 1 receptors, regardless of the synthesis pathway and source of origin of angiotensin II. Due to the specific antagonism of the drug in relation to AT 1-receptors of angiotensin II, the activity of renin, angiotensin I and angiotensin II in plasma increases, and the plasma concentration of aldosterone also decreases.

In patients with arterial hypertension under the influence of Cardosal 20, a prolonged dose-dependent decrease in blood pressure is observed. There is no evidence that hypotension develops after the first dose. There is also no evidence on the occurrence of tachyphylaxis during prolonged therapy or on withdrawal syndrome after discontinuation of treatment (manifested by a sharp increase in blood pressure).

As a result of taking olmesartan once a day, a mild and effective decrease in blood pressure is provided for 24 hours, and the effectiveness of a single dose is similar to the effect of the drug when taken twice a day at the same daily dose.

The hypotensive effect of Cardosal 20 usually develops after 2 weeks, and approximately 8 weeks after the start of treatment, the maximum antihypertensive effect is observed.


Olmesartan medoxomil is a prodrug that, under the action of intestinal enzymes and during absorption from the gastrointestinal tract, in the portal blood, is converted into olmesartan (an active metabolite). In blood plasma and / or feces, unchanged olmesartan medoxomil or olmesartan with an intact medoxomil site is absent. On average, the bioavailability of olmesartan is 25.6%.

The maximum plasma concentration of the active metabolite is reached approximately 2 hours after oral administration and increases almost linearly with an increase in a single dose of Cardosal 20 to 80 mg. Food intake practically does not affect the bioavailability of the active substance, so the drug can be taken at any time, regardless of the time of the meal.

Up to 99.7% of olmesartan binds to plasma proteins, while the shift in this indicator when interacting with other drugs and substances with a high degree of binding to blood plasma proteins is insignificant (this fact is confirmed by the absence of clinically significant interaction with warfarin). Olmesartan hardly binds to blood cells. After its intravenous administration, the average volume of distribution is 16 to 29 liters.

Plasma clearance is typically 1.3 L / h (with a coefficient of variation of 19%). It is quite low compared to the blood flow in the liver, which is 90 l / h.

Olmesartan is excreted by the kidneys (about 40% of the absorbed substance) and through the hepatobiliary system (about 60%). There are no other metabolites other than olmesartan. Intestinal hepatic recirculation of the active metabolite is minimal. Since the main part of the drug is excreted through the liver, it is contraindicated in patients with obstruction of the biliary tract.

After repeated oral administration, T 1/2 of olmesartan is 10 to 15 hours. After taking the first few doses of Cardosal 20, an equilibrium state is achieved. After 14 days of daily use, no further accumulation of olmesartan is observed. Clearance in the kidneys averages 0.5–0.7 l / h and does not depend on the dose taken.

The pharmacokinetics of olmesartan in patients of different sex does not have clinically significant differences.

In renal failure, AUC (area under the concentration-time curve) increases by 62, 82 and 179% in patients with mild, moderate and severe renal failure, respectively (when compared with the same indicator in healthy volunteers).

In individuals with mild and moderate hepatic insufficiency, after a single oral administration of the drug, the AUC of olmesartan increased by 6% and 65%, respectively. After repeated administration of Cardosal, 20 AUC of olmesartan in patients with moderate hepatic impairment is 65% higher than in healthy volunteers. The mean values of the maximum plasma concentration in healthy people and patients with hepatic insufficiency were similar. The pharmacokinetic parameters of the drug have not been studied in patients with severe hepatic impairment.

In elderly and senile age (65 years and older) in patients with arterial hypertension, when the equilibrium state was reached, the AUC of olmesartan increased by 35% (in persons aged 65-75 years) and by 44% (in patients older than 75 years), according to compared with younger patients. Perhaps these differences were due to age-related decline in renal function.

Indications for use

Cardosal 20 is used to treat essential (primary) hypertension.



  • severe renal failure (creatinine clearance is less than 20 ml / min);
  • severe hepatic impairment (more than 9 points on the Child-Pugh scale);
  • condition after kidney transplantation (since there is no experience of clinical use of the drug after kidney transplantation);
  • obstruction of the biliary tract;
  • lactase deficiency, hereditary galactose intolerance, glucose-galactose malabsorption (since the tablets contain lactose);
  • co-administration with aliskiren and aliskiren-containing drugs in patients with diabetes mellitus and / or patients with impaired renal function (creatinine clearance less than 60 ml / min);
  • period of pregnancy and lactation;
  • children and adolescents up to 18 years old;
  • hypersensitivity to the active substance or auxiliary components of the drug.

Relative (Cardosal 20 is used with caution):

  • mild and moderate renal failure (creatinine clearance value more than 20 ml / min);
  • moderate hepatic impairment (less than 9 points on the Child-Pugh scale);
  • chronic heart failure;
  • Ischemic heart disease (coronary heart disease);
  • stenosis of the mitral or aortic valves;
  • bilateral stenosis of the renal arteries or stenosis of the renal artery of a single kidney (vasorenal hypertension);
  • hypertrophic obstructive cardiomyopathy;
  • cerebrovascular diseases;
  • hyponatremia and / or hyperkalemia (due to the risk of arterial hypotension, dehydration and renal failure);
  • conditions leading to a decrease in the volume of circulating blood (for example, vomiting and diarrhea);
  • adherence to a diet with a limited content of table salt;
  • Connes syndrome (primary aldosteronism);
  • simultaneous use with lithium preparations and diuretics;
  • advanced age (patients over 65 years old).

Cardosal 20, instructions for use: method and dosage

Cardosal 20 is taken orally, regardless of the meal time. The tablet should not be chewed, but should be swallowed whole with plenty of water or other liquid. The drug is taken once a day, preferably at the same time.

The initial dose is 10 mg once a day. If the desired decrease in blood pressure is not achieved, you can increase the dose to 20 mg per day. In the future, if necessary, the daily dose is increased to 40 mg. To select a dose, you can use different dosages of the drug (Cardosal 10, Cardosal 20 or Cardosal 40).

The maximum dose is 40 mg per day.

Patients over the age of 65 should be treated with careful blood pressure monitoring.

With mild to moderate renal failure (creatinine clearance from 20 to 60 ml / min), the maximum daily dose of the drug is 20 mg (in patients with severe renal failure, olmesartan medoxomil is not used).

For patients with mild hepatic impairment, the drug is prescribed in usual doses. With moderate hepatic impairment, the initial daily dose is 10 mg, the maximum is 20 mg. In the case of simultaneous use with diuretics and / or other antihypertensive drugs in patients with hepatic insufficiency, it is necessary to monitor renal function and blood pressure. In severe hepatic impairment, Cardosal 20 is contraindicated.

Side effects

  • gastrointestinal tract: often - dyspeptic disorders, nausea, gastroenteritis, diarrhea, abdominal pain; infrequently - vomiting;
  • metabolism and nutrition: often - an increase in the plasma concentration of triglycerides and uric acid; rarely - an increase in the content of potassium in the blood;
  • cardiovascular system: infrequently - angina pectoris; rarely - a significant decrease in blood pressure;
  • respiratory system: often - rhinitis, pharyngitis, cough, bronchitis;
  • nervous system and sensory organs: often - headache, dizziness; infrequently - vertigo;
  • urinary system: often - urinary tract infections, an increase in the number of red blood cells in the urine; rarely - renal failure, including acute;
  • lymphatic system and blood: infrequently - thrombocytopenia;
  • musculoskeletal system: often - arthritis, pain in the bones and back; infrequently - muscle pain; rarely - muscle cramps;
  • skin and subcutaneous fat: infrequently - allergic dermatitis, skin rash, exanthema, itching, urticaria; rarely - Quincke's edema;
  • immune system: infrequently - anaphylactic and anaphylactoid reactions;
  • laboratory test indicators: often - an increase in the activity of liver enzymes, an increase in the content of urea and creatine phosphokinase in the blood; rarely - an increase in the plasma concentration of creatinine;
  • other reactions: often - flu-like symptoms, chest pain, weakness, peripheral edema; infrequently - malaise, asthenia, swelling of the face; rarely - a feeling of drowsiness; isolated cases - rhabdomyolysis.


Overdose data on Cardosal 20 are very limited. The main symptom is a marked decrease in blood pressure.

The patient should be laid in a horizontal position (on his back), slightly lifting his legs. It is recommended to flush the stomach and / or give the patient activated charcoal. Further treatment should be aimed at replenishing the circulating blood volume and correcting violations of the water-electrolyte balance. The effectiveness of dialysis for the elimination of olmesartan has not been studied.

special instructions

Before starting therapy with Cardosal 20, it is necessary to eliminate the factors that contribute to an additional decrease in blood pressure (intensive diuretic treatment, vomiting, diarrhea, limited consumption of table salt).

In some patients, renal function and vascular tone depend on the activity of the RAAS to a greater extent than in others (for example, with severe chronic heart failure or renal artery stenosis). In such patients, the concomitant use of other drugs that affect the RAAS can lead to the development of oliguria, azotemia, acute arterial hypotension or acute renal failure (rarely).

With the use of angiotensin II receptor antagonists, the possibility of a similar therapeutic effect cannot be excluded.

In patients with vasorenal hypertension who receive drugs that affect the RAAS, the risk of renal failure and severe arterial hypotension is increased.

In case of impaired renal function during treatment with Cardosal 20, it is recommended to periodically monitor the level of creatinine and the content of potassium in the blood plasma.

Hyperkalemia, which sometimes develops with treatment with angiotensin II receptor antagonists or ACE (angiotensin converting enzyme) inhibitors, can be fatal. The risk of its occurrence increases with renal failure, dehydration, metabolic acidosis, diabetes mellitus, acute decompensation of cardiac activity, conditions that are accompanied by massive cell lysis (extensive trauma, rhabdomyolysis, acute limb ischemia), when used together with drugs that increase the plasma potassium concentration, as well as in old age.

Appointment of Cardosal 20 simultaneously with other drugs that affect the RAAS is possible only after a careful assessment of the balance of benefits and risks of this combination. Consideration of other treatment options is recommended.

In patients of the Negroid race, the efficacy of olmesartan medoxomil therapy is slightly lower than in other races, which is apparently due to the greater prevalence of low plasma renin activity in this population.

An excessive decrease in blood pressure in patients with cerebrovascular insufficiency or ischemic heart disease can lead to stroke or myocardial infarction.

Influence on the ability to drive vehicles and complex mechanisms

During the period of treatment with Cardosal 20, side reactions such as weakness and drowsiness may occur, therefore, when driving a car or other vehicles, as well as during other potentially hazardous activities, care must be taken.

Application during pregnancy and lactation

There is no experience of using the drug in pregnant women. However, it is known that drugs that directly affect the RAAS have a severe teratogenic effect, therefore, Cardosal 20 is contraindicated during pregnancy. If pregnancy occurs during treatment with the drug, it should be immediately canceled and another, alternative therapy should be prescribed.

For women planning pregnancy, it is advisable to select antihypertensive drugs from other groups, the safety of which during pregnancy has been proven by appropriate studies. The exception is when the use of angiotensin II receptor antagonists is vital.

Pregnant women who have taken angiotensin II receptor antagonists in the II and III trimesters should undergo an ultrasound examination of the fetus to assess ossification of the skull bones and kidney function. Newborns whose mothers took drugs in this group should be examined for possible impairment of renal function and the development of arterial hypotension.

It is not known whether the drug is secreted in human breast milk. There is reliable data on the penetration of olmesartan into the breast milk of rats. Therefore, during lactation, Cardosal 20 is contraindicated.

Pediatric use

In patients under 18 years of age, Cardosal 20 is not used due to the lack of data on the efficacy and safety of olmesartan medoxomil use in childhood.

With impaired renal function

Olmesartan medoxomil is contraindicated in severe renal impairment (creatinine clearance less than 20 ml / min). With a creatinine clearance of 20 to 60 ml / min, Cardosal 20 is used with caution.

For violations of liver function

Cardosal 20 is contraindicated in patients with severe liver dysfunction and obstruction of the biliary tract.

Use in the elderly

In patients aged 65 years and older, Cardosal 20 is used with caution.

Drug interactions

Cardosal 20 is not recommended to be taken simultaneously with potassium preparations, potassium-containing salt substitutes, potassium-sparing diuretics and other drugs that increase the plasma concentration of potassium (for example, immunosuppressants, selective cyclooxygenase-2 inhibitors, heparin, ACE inhibitors, etc.), since this can lead to hyperkalemia. …

The antihypertensive effect of olmesartan is usually enhanced when used together with other drugs to lower blood pressure.

Cyclooxygenase-2 inhibitors, non-steroidal anti-inflammatory drugs (including acetylsalicylic acid in doses of more than 3 g per day) and angiotensin II receptor antagonists are able to synergize and reduce glomerular filtration. In the case of a combination of olmesartan with non-steroidal anti-inflammatory drugs, the likelihood of acute renal failure increases, therefore, at the beginning of joint therapy, it is recommended to monitor renal function and consume a sufficient amount of fluid. In addition, with simultaneous use, it is possible to reduce the antihypertensive activity of angiotensin II receptor antagonists and to partially lose their therapeutic effect.

Coadministration with lithium preparations is not recommended (due to a possible reversible increase in serum lithium concentration and an increase in its toxicity).

Antacids (magnesium hydroxide and aluminum hydroxide) may moderately reduce the bioavailability of olmesartan.

Cardosal 20 should not be used concurrently with aliskiren, aliskiren-containing drugs and ACE inhibitors, since with a double blockade of the RAAS, the incidence of hyperkalemia, arterial hypotension and decreased renal function is higher than in the case of therapy with only one drug from the listed drugs.

Aliskiren-containing drugs cannot be combined with olmesartan medoxomil in patients with renal insufficiency and diabetes mellitus. Patients with diabetic nephropathy should not be simultaneously prescribed ACE inhibitors.

There was no clinically significant interaction with digoxin, pravastatin, warfarin and hydrochlorothiazide.


The analogues of Cardosal 20 are Angiakand, Valsakor, Diovan, Zisakar, Irbesartan, Kandekor, Cardosal 10, Cardosal 40, Candesartan-SZ, Losartan, Mikardis, Renicard, Telmisartan, etc.

Terms and conditions of storage

Keep out of the reach of children. Store in a dark place at a temperature not exceeding 30 ° C.

The shelf life of the drug is 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Cardosal 20

There are not many reviews of Cardosal 20. Patients note that the drug reduces and stabilizes blood pressure well, and is suitable for long-term use. It is convenient to take the tablets (a sufficient single dose per day).

The main disadvantage, according to doctors and patients, is the frequent occurrence of side effects, including persistent weakness and chest pain.

Price for Cardosal 20 in pharmacies

The price of Cardosal 20 in the form of film-coated tablets, 20 mg (28 pcs. In a package) averages 590-750 rubles.

Cardosal 20: prices in online pharmacies

Drug name



Cardosal 20 20 mg film-coated tablets 28 pcs.

554 r


Anna Kozlova
Anna Kozlova

Anna Kozlova Medical journalist About the author

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!

Popular by topic